Antibody Drug Discovery for Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 351
Special Issue Editor
Special Issue Information
Dear Colleagues,
Characterized by an excellent specificity, high-level affinity, long serum half-life, and immune effector function, antibodies have been a powerful weapon against cancer since the approval of the first antibody drug (rituximab) in 1997. The predominant anticancer monoclonal antibody approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is IgG. Some alternative formats for approved antibody drugs include antibody-drug conjugates and bispecific antibodies. The successful application of antibody drugs in oncology has encouraged the development of next-generation antibodies with an enhanced response. The global antibody drug market is rapidly expanding.
This Special Issue “Antibody Drug Discovery for Cancer” aims to publish original research and review articles focused on (but not limited to) the development of new monoclonal antibodies, nanobodies, ADCs, and bispecific antibodies for cancer treatment. Meanwhile, papers related to the translation of antibody drugs and evaluations in clinical trials are welcomed.
Dr. Junquan Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- immunotherapy
- monoclonal antibody
- nanobody
- bispecific antibody
- antibody drug conjugate
- clinical trial
